SEC Filings | Aerie Pharmaceuticals, Inc
Aerie-Pharma -
Aerie Pharma: Finding Value In The Ophthalmic Space (NASDAQ:AERI) | Seeking Alpha
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Durham-based Aerie Pharma sees positive study results for eye pressure drug | WRAL TechWire
Aerie Pharmaceuticals and Ramot at Tel Aviv University Enter Research Collaboration | Business Wire
AERIE PHARMACEUTICALS, INC. : AERI Stock Price | MarketScreener
Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Program
Aerie Pharma: 80% Upside While The Moon Shot Awaits (NASDAQ:AERI) | Seeking Alpha
Rx Item-RHOPRESSA 0.02 % O/S 2.5 ML netarsudil mesylate DROPS BY AERIE PHARMA
Investor Relations | Aerie Pharmaceuticals, Inc
Should Aerie Pharmaceuticals Inc (AERI) be in Your Portfolio? - InvestorsObserver
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharmaceuticals Inc - AnnualReports.com
Aerie Pharmaceuticals – Capital Sign Solutions
Durham's Aerie Pharma raises $316.5M, to use funds for eye disease drug development | WRAL TechWire
Aerie
Aerie Pharma: Significantly Derisked (NASDAQ:AERI) | Seeking Alpha
Compliance Program | Aerie Pharmaceuticals, Inc.
Aerie Pharma's CMO Receives FDA CRL - Contract Pharma
Cantor Initiates Aerie Pharma At Buy: 'Wouldn't Be Surprised If Aerie Became Takeover Candidate'
Aerie Pharmaceuticals Launches GMP Facility - Contract Pharma
Aerie in Europe - EuroTimes
Aerie Pharmaceuticals, Inc.
Eye disease drug firm Aerie Pharma acquires Spanish company for $10M | WRAL TechWire
